reports
Aekyung Chemical: 1 director
A director at Aekyung Chemical sold 2,100 shares at 14,000.000KRW and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Healthcare Co Ltd: 1 director
A director at Healthcare Co Ltd bought 1,257,100 shares at 8.510CNY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
WisdomTree Reports Monthly Metrics for April 2024
NEW YORK--(BUSINESS WIRE)-- WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for April 2024, including assets under management (AUM) and flow data by asset class. Monthly Commentary: WisdomTree has over $1.4 billion of net inflows year-to-date despite ~$570 million of net outflows for the month of April WisdomTree’s U.S. listed ETFs and offshore UCITS ETF suite generated a combined $484 million of net inflows in April and have gathered $2.8 billion of net inflows year-to-date in 2024 (an 11% annualized pace of year-to-date organic growth) Wis...
Prime Medicine Reports First Quarter 2024 Financial Results and Provid...
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates -- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 -- -- Appointed Tony Coles, M.D. as senior advisor -- CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnol...
Whitestone REIT Urges Shareholders to Support Its Highly Qualified Tru...
Whitestone REIT Urges Shareholders to Support Its Highly Qualified Trustee Nominees at the Annual Meeting on May 14 – Vote Today Using the White Proxy Card Whitestone’s Turnaround Strategy Has Been Successful Under New Board / Leadership Team Our Reset Strategy Has Momentum and the Market Is Recognizing Our Accomplishments Do Not Let Erez Interrupt Our Momentum, Derail Our Strategy and Destroy Value Glass Lewis and Egan Jones, Two Leading Proxy Advisory Firms, Both Recommended that Shareholders Vote "FOR ALL" of Whitestone's Board Nominees on the WHITE Proxy Card HOUSTON...
Creative Realities Reports Fiscal 2024 First Quarter Results
Creative Realities Reports Fiscal 2024 First Quarter Results Strong Revenue Growth, Refinancing Underway, 2024 Outlook Reaffirmed LOUISVILLE, Ky., May 10, 2024 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced its financial results for the fiscal first quarter ended March 31, 2024. Highlights: Record first quarter revenue of $12.3 million, up 24% from $9.9 million in the prior-year periodGross profit of $5.8 million for the three months ended March 31, 2024 ...
Eezy Plc - Manager's Transactions - DG Holding Oy
Eezy Plc - Manager's Transactions - DG Holding Oy EEZY PLC -- MANAGERS TRANSACTIONS -- 10 MAY 2024 AT 15:00 Eezy Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: DG Holding OyPosition: Member of the Board/Deputy member(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Markus JussilaPosition: Other senior managerIssuer: Eezy OyjLEI: 743700ZKOMTB7X00OW54Notification type: INITIAL NOTIFICATIONReference number: 62245/10/10____________________________________________Transaction da...
Eezy Oyj - Johdon liiketoimet - DG Holding Oy
Eezy Oyj - Johdon liiketoimet - DG Holding Oy EEZY OYJ -- JOHDON LIIKETOIMET -- 10.5.2024 klo 15:00 Eezy Oyj - Johdon liiketoimet ____________________________________________IlmoitusvelvollinenNimi: DG Holding OyAsema: Hallituksen jäsen/varajäsen(X) Oikeushenkilö (1):Liikkeeseenlaskijassa johtotehtävissä toimiva henkilöNimi: Markus JussilaAsema: Muu ylin johtoLiikkeeseenlaskija: Eezy OyjLEI: 743700ZKOMTB7X00OW54Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 62245/10/10____________________________________________Liiketoimen päivämäärä: 2024-05-08Kauppapaikka: NASDAQ HELSINK...
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and...
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. “Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™,” said Ge...
Doman Building Materials Group Ltd. Announces Meeting Results for Elec...
Doman Building Materials Group Ltd. Announces Meeting Results for Election of Directors THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Doman Building Materials Group Ltd. (“Doman”) or the “Company”) (TSX:DBM) announced its director election results following its annual and special meeting of shareholders, held May 9, 2024. All of the nominees proposed as directors in the Company's Management Informatio...
Mobile-health Network Solutions Expands Services to Malaysia
Mobile-health Network Solutions Expands Services to Malaysia SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the establishment of a subsidiary in Malaysia. This strategic expansion signifies MNDR's commitment to delivering accessible and affordable healthcare services throughout Southeast Asia. Solidifying Regional Leadership The Malaysian subsidiary marks a pivotal step in the Company’s growth trajectory. It positions the Company as a fro...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Dev...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in viv...
Dycom Industries, Inc. to Host Fiscal 2025 First Quarter Results Confe...
Dycom Industries, Inc. to Host Fiscal 2025 First Quarter Results Conference Call PALM BEACH GARDENS, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2025 first quarter results on Wednesday, May 22, 2024, at 9:00 a.m. Eastern time. Dycom will issue a press release reporting its results earlier that morning. Interested parties may participate in the question and answer session of the conference call by registering at . Upon registration, participants will receive a dial-in number and unique PIN to access the call. Parti...
Praxis Precision Medicines to Report First Quarter 2024 Financial Resu...
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical...
Ekso Indego Personal to be Featured on ‘Health Uncensored’ with Dr. Dr...
Ekso Indego Personal to be Featured on ‘Health Uncensored’ with Dr. Drew Pinsky Segment to appear on Fox Business News on Sunday, May 12 at 5:30 p.m. ET SAN RAFAEL, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the Ekso Indego Personal will be featured on ‘Health Uncensored’ hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Fox Business News channel on Sunday, May 12 at 5:30 p.m. ET / 2:30 p.m. PT. Scott Dav...
Liquidia Announces Poster Presentation at the American Thoracic Societ...
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (AT...
Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify...
Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify Strategic Partnerships and Potential Acquisitions Renowned Industry Leader and Smart for Life Board Member Heather Granato to Speak at Nutraceutical Event in Geneva, Switzerland MIAMI, May 10, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing of nutritional supplements and foods, today announced its participation in Vitafoods Europe 2024, scheduled to take place in Gen...
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gros...
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common s...
Shenzhen Kingdom Sci-tech Co Ltd: 1 director
A director at Shenzhen Kingdom Sci-tech Co Ltd bought 170,000 shares at 11.250CNY and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 1,000,000 shares at 1.030SGD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.